Nav: Home

Head injury effects halted by xenon gas, finds first ever life-long study in mice

May 21, 2019

TBI is the leading cause of death and disability in people under 45 in developed countries. The primary injury, caused by the initial force from a fall or car accident for example, is followed by a secondary injury which develops in the minutes, hours and days afterwards.

This secondary injury is largely responsible for the mental and physical disabilities associated with TBI - but there are currently no specific drug treatments that can be given after the trauma to stop it from developing.

TBI patients who survive the injury have a reduced life expectancy and an increased risk of developing Alzheimer's disease or other dementias later in life.

Now, researchers from Imperial College London and Johannes Gutenberg University Mainz have found that the anaesthetic drug xenon, given shortly after a TBI, prevents early death and long-term cognitive impairment and protects brain tissue itself in mice. The xenon-treated mice had a similar life expectancy, cognitive function, and brain tissue integrity, to mice that had never sustained a TBI.

Previously, the same team led by Dr Robert Dickinson and colleagues at Imperial's Department of Surgery & Cancer, showed xenon limited early brain damage and improved long-term motor function in mice with TBI. However, they had yet to look at xenon's effect on life expectancy, long-term cognitive function and brain tissue degeneration after TBI.

This new study, published in the British Journal of Anaesthesia, looked at the effects of xenon over the whole lifespan of mice for the first time.

Animals were randomly allocated to one of three groups: TBI xenon, TBI control, and healthy control. Under general anaesthesia, and with long-acting pain relief, a controlled mechanical force was applied to the brains of the TBI control and TBI xenon groups. The healthy control group was given anaesthesia, but did not receive a TBI. The researchers gave xenon gas to one of these groups (TBI xenon group), while the other two received control gas for the same amount of time.

All three groups then underwent learning and memory tests at two weeks and 20 months after injury. The researchers also recorded their time of death and examined their brain tissues.

They found that:
  • The TBI xenon group had the same life expectancy as the healthy control group which had not suffered a TBI.
  • The TBI control group developed late-onset cognitive damage. Xenon treatment shortly after TBI appeared to prevent this.
  • Key brain areas involved in cognitive functioning were damaged in control TBI group. Xenon-treatment prevented or significantly reduced this damage.
  • Xenon prevented the loss of brain cells in the hippocampus (an area of the brain associated with learning and memory), and prevented degeneration of nerve fibres in the corpus callosum (which connects the two brain hemispheres) that may explain the improvement in cognitive function (see images in Notes to Eds.) Xenon was also shown to reduce long-term brain inflammation that is believed to be involved in cognitive impairment in Alzheimer's Disease and other dementias.
According to the group, the findings are important as they could offer insight into new treatments for patients with TBI. Patients with TBI early in life are eight times more likely to die early than people without and are more likely to develop Alzheimer's Disease and other types of dementia later on. There is currently no specific drug treatment available for people who suffer a TBI - instead, the treatment is supportive and rehabilitative.

Lead author of the study, Dr Rita Campos-Pires, from the Department of Surgery & Cancer, said: "There is currently a huge gap in what treatment we can offer to patients who've suffered TBI - an injury which can impact all areas of their lives.

"Although xenon has not yet been tested for TBI in humans, our findings add to the growing body of evidence that suggests it could be used after head injuries to prevent secondary injury developing.

"Xenon appears to act in a variety of ways, but one of the most likely mechanisms to explain its protective effects on brain tissue is by inhibiting receptors in the brain known as NMDA receptors, that become over-activated following a brain injury."

Dr Dickinson added: "We have looked at very long-term outcomes, up to 20 months after TBI in mice. This is very rarely done in animal studies and is equivalent to following up human TBI patients until their 80s. The finding that only a short treatment with xenon can have beneficial effects on cognition, survival, and brain damage almost two years later suggests that xenon might in future prevent cognitive decline and improve survival in human TBI patients."

Xenon is already used as a human general anaesthetic, is known to have few side effects and could be easily given via inhalation or to mechanically ventilated TBI patients in the intensive care unit. Given xenon's safety profile - and today's findings - the researchers hope in future to evaluate the effectiveness of xenon in human TBI patients.
This study was funded by the Medical Research Council, the European Society for Anaesthesiology, the National Institute for Academic Anaesthesia, the Association of Anaesthetists of Great Britain & Ireland, and the Gas Safety Trust.

Imperial College London

Related Cognitive Impairment Articles:

USPSTF statement on screening for cognitive impairment in older adults
The US Preventive Services Task Force (USPSTF) concludes that current evidence is insufficient to make a recommendation about screening for cognitive impairment in adults 65 or older.
Scientists discover link between autism and cognitive impairment
Scientists have found how a single gene fragment impacts social behaviour and cognitive ability, revealing a common molecular mechanism for autism and Fragile X syndrome.
Mild cognitive impairment, ISS produces the first epidemiological estimation
In a study published in the Journal of Alzheimer's Disease, ISS researchers estimated about 680,000 cases of mild cognitive impairment (MCI), in a total of 12,730,960 migrants, aged between 60 and 89 years, living in the European Union (EU) in 2018.
Research underscores value of cognitive training for adults with mild cognitive impairment
Researchers at the Center for BrainHealth®, part of The University of Texas at Dallas, combined two non-pharmacological interventions for adults with Mild Cognitive Impairment (MCI): eight sessions of Strategic Memory Advanced Reasoning Training (SMART), a cognitive training program shown to improve reasoning and ability to extract bottom-line messages from complex information; and Transcranial Direct Current Stimulation (tDCS) over the left frontal region, associated with cognitive control and memory recovery success in people with Alzheimer's.
Kidney disease triggers cognitive impairment, even in early stages
Chronic kidney disease (CKD) is increasingly recognized as a systemic condition.
Lowering blood pressure reduces risk of cognitive impairment
Intensive control of blood pressure in older people significantly reduced the risk of developing mild cognitive impairment (MCI), a precursor of early dementia, in a clinical trial led by scientists at Wake Forest School of Medicine, part of Wake Forest Baptist Health.
Advances in the study of drugs to combat cognitive impairment in schizophrenia
A study by the UPV/EHU has assessed the effectiveness of various drugs, which are used to delay cognitive deterioration in patients with Alzheimer's, in improving cognitive impairment displayed by patients with schizophrenia.
Antioxidants may prevent cognitive impairment in diabetes
Cognitive difficulties in patients with diabetes, caused by repeated episodes of low blood sugar, could be reduced with antioxidants, according to a new study presented at the Society for Endocrinology annual conference in Glasgow.
Visual impairment associated with a decline in cognitive function
Worsening vision and declining cognitive function are common conditions among older people.
What if you could know that your mild cognitive impairment wouldn't progress
Researchers from the Lisbon School of Medicine, University of Lisbon found that, in some mild cognitive impairment patients, real neuropsychological stability over a decade is possible and that long-term stability could be predicted based on neuropsychological tests measuring memory and non-verbal abstract reasoning.
More Cognitive Impairment News and Cognitive Impairment Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

One of the most consistent questions we get at the show is from parents who want to know which episodes are kid-friendly and which aren't. So today, we're releasing a separate feed, Radiolab for Kids. To kick it off, we're rerunning an all-time favorite episode: Space. In the 60's, space exploration was an American obsession. This hour, we chart the path from romance to increasing cynicism. We begin with Ann Druyan, widow of Carl Sagan, with a story about the Voyager expedition, true love, and a golden record that travels through space. And astrophysicist Neil de Grasse Tyson explains the Coepernican Principle, and just how insignificant we are. Support Radiolab today at